Clinical Trials at START Midwest
As of September 2026, 63 paid clinical trials are recruiting at START Midwest, located at 750 FRONT AVE NW STE 311, GRAND RAPIDS, MI 49504-4400, phone (616) 459-8971 in Grand Rapids, Michigan. Active studies at this site cover conditions such as Colorectal Cancer, Advanced Solid Tumors and Ovarian Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Grand Rapids
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
DBC-664 in Adult Patients With Solid Tumors
67 clinical trials at START Midwest
·Clear filters·A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
Study of GS-2426 in Participants With Advanced Solid Tumors
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
TLN-372 in Advanced KRAS Mutant Solid Tumors
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Common conditions studied in Grand Rapids
- Colorectal Cancer (17 active studies)
- Advanced Solid Tumors (16 active studies)
- Ovarian Cancer (11 active studies)
- Advanced Solid Tumor (10 active studies)
- Breast Cancer (9 active studies)
- Endometrial Cancer (9 active studies)
Leading research sponsors in Grand Rapids
- National Cancer Institute (NCI)
- Children's Oncology Group
- SWOG Cancer Research Network
- AstraZeneca
- Merck Sharp & Dohme LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in Grand Rapids?
There are approximately 422 recruiting clinical trials in Grand Rapids, Michigan listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Grand Rapids pay participants?
Most recruiting trials in Grand Rapids compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Grand Rapids?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Grand Rapids?
The most common conditions under active study in Grand Rapids include Colorectal Cancer (17), Advanced Solid Tumors (16), Ovarian Cancer (11), Advanced Solid Tumor (10), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Grand Rapids?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Grand Rapids on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Grand Rapids?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Grand Rapids?
Recruiting research sites in Grand Rapids include START Midwest, Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Grand Rapids right now?
The largest active categories in Grand Rapids are Cancer & tumors (226), Cardiovascular (20), Neurology & pain (10). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of START Midwest?
START Midwest is located at 750 FRONT AVE NW STE 311, GRAND RAPIDS, MI 49504-4400. Use the Google Maps link in the intro above to get directions.
How do I contact START Midwest?
You can reach START Midwest by phone at (616) 459-8971. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.